Prognostic significance of nonfatal reinfarction during 3-year follow-up: Results of the thrombolysis in myocardial infarction (TIMI) phase II clinical trial

Journal of the American College of Cardiology

Volumn 26, Issue 4, 1995, Pages 900-907

  Mueller, Hiltrud S ^a   Forman, Sandra A ^a,b   Menegus, Mark A ^a   Cohen, Lawrence S ^a,c   Knatterud, Genell L ^a,b   Braunwald, Eugene ^a,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HEPARIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD CLOT LYSIS; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART REINFARCTION; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

AGED; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIFE TABLES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PLASMINOGEN ACTIVATORS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0028886354     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(95)00270-1     Document Type: Article

References (45)

1. The Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction
2. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
3. Randomised trial of intravenous streptokinase oral aspirin both or neither among 17187 cases of suspected acute myocardial infarction ISIS-2
4. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET)
5. A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction
6. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin
7. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
8. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction
9. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
10. An approach to evaluating thrombolytic therapy in acute myocardial infarction: the “unsatisfactory outcome” end point
11. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials
12. Nonfatal cardiac events and recurrent infarction in the year after acute myocardial infarction
13. Factors associated with recurrent myocardial infarction within one year after acute myocardial infarction
14. Prognostic significance of nonfatal myocardial reinfarction
15. Prognosis after recovery from first acute myocardial infarction: determinants of reinfarction and sudden death
16. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction results of the thrombolysis in myocardial infarction (TIMI) phase II trial
17. Immediate versus delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction
18. Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B study
19. Two- and three-year results of the Thrombolysis In Myocardial Infarction (TIMI) phase II clinical trial
20. Nonparametric estimation from incomplete observations
21. Regression models and life tables
22. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction: analyses of patient subgroups in the Thrombolysis In Myocardial Infarction (TIMI) trial, phase II
23. GISSI-2 a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction
24. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non Q-wave myocardial infarction results of the TIMI IIIB trial
25. One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial
26. A pilot trial of recombinant desulfatohirudin compared to heparin in conjunction with tissue plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 5 trial
27. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction
28. Predictors of nonfatal reinfarction in survivors of myocardial infarction after thrombolysis results from the GISSI-2 data base
29. One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial
30. Two-year outcome after angiographically documented myocardial reperfusion for acute coronary occlusion
31. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study
32. Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction
33. More on Survival and Ventricular Enlargement trial
34. Recurrent ischemia without warning: analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator
35. Consequences of reocelusion after successful reperfusion therapy in acute myocardial infarction
36. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator
37. Early angiography cannot predict postthrombolytic coronary reocclusion observations from the GUSTO Angiographic study
38. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: experience gleaned from the international tissue plasminogen activator/streptokinase mortality trial
39. Smoking and mortality among older men and women in three communities
40. Prognosis after recovery from myocardial infarction: the relative importance of cardiac dilatation and coronary stenoses
41. The risk of myocardial infarction after quitting smoking in men under 55 years of age
42. Six-month survival in 20891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin
43. Prognosis and management after a first myocardial infarction